SCHEMBL858832

SCHEMBL858832

Nc1nc2ncccn2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
CSF1R P07333 1/20 0.46
RET P07949 1/20 0.46
GRK5 P34947 1/20 0.46
MAPK8 P45983 1/20 0.46
CSNK1A1 P48729 1/20 0.46
ACVR1 Q04771 1/20 0.46
PTK2 Q05397 1/20 0.46
TYRO3 Q06418 1/20 0.46
MAP4K2 Q12851 1/20 0.46
DYRK1A Q13627 1/20 0.46
IKBKE Q14164 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
PIK3CD O00329 1/20 0.46
PIK3CB P42338 1/20 0.46
PIK3CG P48736 1/20 0.46
PDE10A Q9Y233 2/20 0.45
RAB9A P51151 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL10558548 0.80 ALDH1A1 (0.40) MAP4K4PAK4CSF1RRETGRK5
SCHEMBL2668952 0.77 PDE10A (0.47) PIK3CGPDE10ARAB9ANPC1ALDH1A1
SCHEMBL7195074 0.75 PDE10A (0.45) PIK3CGPDE10ARAB9ANPC1ALDH1A1
SCHEMBL12989975 0.75 PDE10A (0.45) PIK3CGPDE10ARAB9ANPC1ALDH1A1
SCHEMBL21389568 0.75 PDE10A (0.45) DYRK1APIK3CGPDE10ARAB9ANPC1
SCHEMBL259293 0.75 PDE10A (0.45) PIK3CGPDE10ARAB9ANPC1ALDH1A1
SCHEMBL9933090 0.75 PDE10A (0.45) PIK3CGPDE10ARAB9ANPC1ALDH1A1
SCHEMBL10921639 0.75 PDE10A (0.45) PIK3CGPDE10ARAB9ANPC1ALDH1A1
SCHEMBL5225420 0.72 NPC1 (0.40) PDE10ARAB9ANPC1ALDH1A1KDM4E
SCHEMBL9101730 0.72 ALDH1A1 (0.55) RAB9ANPC1ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220378794-A1 TREATING COGNITIVE DISORDERS USING TRAPIDIL SINOPIA BIOSCIENCES, INC. 2022-12-01 US claimed
EP-4069239-A1 TREATING COGNITIVE DISORDERS USING TRAPIDIL Sinopia Biosciences, Inc. (US) 2022-10-12 EP claimed
US-20070129383-A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-06-07 US claimed
EP-1674454-A1 SUBSTITUTED 2-AMINO- 1,2,4 TRIAZOLO 1,5-a PYRIMIDINE DERIVATIVE AND USE THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2006-06-28 EP claimed
EP-0717743-B1 N-ARYL 1,2,4]TRIAZOLO 1,5-a]PYRIDINE-2-SULFONAMIDE HERBICIDES DOW AGROSCIENCES LLC (US) 2001-11-14 EP claimed
WO-1996001826-A1 N-ARYL[1,2,4]TRIAZOLO[1,5-a]PYRIDINE-2-SULFONAMIDE HERBICIDES DOWELANCO (US) 1996-01-25 WO claimed
JP-60185782-A None JP disclosed
JP-61165364-A None JP disclosed
US-20250387396-A1 TREATING EXTRAPYRAMIDAL SYNDROME USING TRAPIDIL SINOPIA BIOSCIENCES INC (US) 2025-12-25 US disclosed
EP-3442538-B1 TREATING LEVODOPA-INDUCED DYSKINESIA USING TRAPIDIL SINOPIA BIOSCIENCES INC (US) 2025-07-23 EP disclosed
EP-4217346-B1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-07-02 EP disclosed
US-12268691-B2 Treating extrapyramidal syndrome using trapidil SINOPIA BIOSCIENCES, INC. (US) 2025-04-08 US disclosed
EP-4259626-B1 PROCESS FOR THE PREPARATION 4-(3,5-DIFLUOROPHENYL)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3- AZABICYCLO[3.2.1]OCTAN-8-YL]-6,7-DIHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE HOFFMANN LA ROCHE (CH) 2025-01-29 EP disclosed
US-4638075-A CHEMICAL INTERMEDIATES FOR TRIAZOLO (1,5A) PYRIMIDINES THE DOW CHEMICAL COMPANY (US) 1987-01-20 US disclosed
US-4638075-A CHEMICAL INTERMEDIATES FOR TRIAZOLO (1,5A) PYRIMIDINES THE DOW CHEMICAL COMPANY (US) 1987-01-20 US disclosed
JP-S61165364-A PREPARATION OF HERBICIDAL SULFONAMIDE DERIVED FROM SUBSTITUTED 2-AMINO-1,2,4-TRIAZOLO(1,5-A)PYRIMIDINE AND NOVEL INTERMEDIATE DOW CHEMICAL CO 1986-07-26 JP disclosed
EP-0188225-A1 Process for the preparation of herbicidal sulfonamides derived from substituted 2-amino-1,2,4 triazolo (1,5-a) pyrimidines and novel intermediates provided therein THE DOW CHEMICAL COMPANY (US) 1986-07-23 EP disclosed
JP-S60185782-A COMPOSITION AND PROCESS FOR CONTROLLING NOVEL SULFONAMIDE DERIVED FROM SUBSTITUTED 2-AMINO-1,2,4-TRIAZOLO(1,5-A) PYRIMIDINE AND UNDESIRABLE PLANT DOW CHEMICAL CO 1985-09-21 JP disclosed
EP-0150974-A3 NOVEL SULFONAMIDES DERIVED FROM SUBSTITUTED 2-AMINO-1,2,4-TRIAZOLO(1,5-A)PYRIMIDINES AND COMPOSITIONS AND METHODS OF CONTROLLING UNDESIRED VEGETATION THE DOW CHEMICAL COMPANY (US) 1985-08-21 EP disclosed
EP-0150974-A2 Novel sulfonamides derived from substituted 2-amino-1,2,4-triazolo(1,5-a)pyrimidines and compositions and methods of controlling undesired vegetation THE DOW CHEMICAL COMPANY (US) 1985-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387396-A1 TREATING EXTRAPYRAMIDAL SYNDROME USING TRAPIDIL MAP2K3, JUND, BCL2L13 MAP4K4 69/4885PAK4 1388/4885CSF1R 1289/4885
US-20220378794-A1 TREATING COGNITIVE DISORDERS USING TRAPIDIL SLC6A3, DRD3, DRD2 MAP4K4 1047/4885PAK4 1284/4885CSF1R 4020/4885
US-20070129383-A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof ADORA1, ADORA2B, ADORA3 MAP4K4 1958/4885PAK4 2391/4885CSF1R 3912/4885
US-12268691-B2 Treating extrapyramidal syndrome using trapidil SLC6A3, PARK7, TAC3 MAP4K4 1262/4885PAK4 896/4885CSF1R 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.